Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
Search Engine Sogou Joins Exodus of Chinese Firms From Wall Street as Tencent Takes It Private
Tencent Leads Over $100m Funding in Pet Clinic Operator New Ruipeng
Trending in China: Team Effort VS Individualism - What is the Message Behind Box Office Smash Hit Volleyball Movie Leap?
LATEST
Trending in China: The View from China on U.S. Presidential Election Debate Antics
Trending in China: Disneyland Shanghai Hotel Prices Rocket to Over $1,000 a Night
Chinese Bitcoin Mining Machine Maker Ebang Establishes Canadian Subsidiary
Trending in China: Team Effort VS Individualism - What is the Message Behind Box Office Smash Hit Volleyball Movie Leap?
Tencent Leads Over $100m Funding in Pet Clinic Operator New Ruipeng
Watch Out Alipay and WeChat, Trip.com Is Getting Into Online Payments
Search Engine Sogou Joins Exodus of Chinese Firms From Wall Street as Tencent Takes It Private
Huawei Showcases Smart Car Technologies at Beijing Auto Show
Trending in China: A David and Goliath Battle - Students Take on a Chinese Tech Giant and Win
Chinese Drug Manufacturer InventisBio Bags $147m Led by Hillhouse Capital
Profits of Weibo Soar Even as Revenue Falls
Chinese Electric Vehicle Startup Xpeng Receives Investment to Build Production Base in Guangzhou
Video Site Operator Mango Plans to Raise $660 Million to Expand Content Library
Chinese Biotech Firm Creative Biosciences Raises $88m From IDG, CDH, Others
Alibaba’s Ant Group Launches Blockchain-Based Platform to Streamline Cross-Border Trade
Trending in China: Mission Impossible? Young Environmental Hero Tries To Clean Up Tibet
Chinese Online Travel Agency Trip.com Sees Revenue Plummet As Covid-19 Fallout Lingers
Chinese Supply Chain Provider Xingyun Closes $200m in a Series C Round
Chinese EV Charging Operator Star Charge Nabs $125m Co-Led by Schneider, CICC
Trending in China: One of China’s Weirder Poverty Alleviation Programs Goes Viral with 100m Plus Views
China Approves Older Novartis MS Drug

By Matthew Walsh / Jul 20, 2019 05:37 AM / Business & Tech

Photo: VCG

Photo: VCG

Novartis International AG won approval in China to sell its multiple sclerosis (MS) drug Gilenya, Reuters reports, deepening the Swiss pharmaceutical giant's business ties to the huge Chinese health care market and promising to shake up the treatment of what has traditionally been a poorly managed disease there.

MS is the most common autoimmune disease affecting the central nervous system. Around 30,000 people in China live with the condition, according to state news agency Xinhua. That compares with nearly 1 million people in the U.S. suffering the disease, according to a study by the National MS Society.

However, low awareness of MS in China means that the actual number of people with the disease may be significantly higher. In May, Chinese doctors urged both health-care professionals and the general public to learn more about the disease, adding that 95% of people knew nothing about MS before they were diagnosed.

MS occurs when the body’s immune system attacks the fatty sheaths around the nerves, disrupting their ability to send messages to one another. As MS progresses, it causes muscle and cognitive problems and can lead to lasting disabilities.

Although there is no one-size-fits-all cure, a number of treatments can significantly slow the progression of MS. China has long been playing catch-up with Western countries in rolling out such treatments, however, and comparatively few are yet available there.

One such drug, teriflunomide — sold under the trademark Aubagio — was approved by the U.S. Food and Drug Administration in 2012 but gained approval in China only last year.

Gilenya sales earned Novartis $825 million during the second quarter, making it the company’s second-largest source of revenue, Reuters said, adding that the drug has been available in the United States for almost a decade but is now being challenged by generic rivals, spurring Novartis’s push into other markets.

Related: In Depth: Why China’s Drug Review Revamp Is Stalling

Contact reporter Matthew Walsh (matthewwalsh@caixin.com)

Share this article
Open WeChat and scan the QR code